{"nctId":"NCT01347710","briefTitle":"A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.","startDateStruct":{"date":"2011-06"},"conditions":["Coronary Artery Disease"],"count":795,"armGroups":[{"label":"Flurpiridaz F18","type":"EXPERIMENTAL","interventionNames":["Drug: Flurpiridaz F18","Drug: 99mTechnicium (sestamibi or tetrofosmin)"]}],"interventions":[{"name":"Flurpiridaz F18","otherNames":["flurpiridaz F 18"]},{"name":"99mTechnicium (sestamibi or tetrofosmin)","otherNames":["99mTc sestamibi or 99mTc Tetrofosmin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nInvasive Coronary Angiography. Men or Women age 18 or older - see protocol for additional details.\n\nExclusion Criteria:\n\nWomen who are pregnant, lactating, or of child bearing potential who are not practicing birth control.\n\nUnstable cardiac status. History of coronary artery bypass graft. History of percutaneous coronary intervention within the past six months. See protocol for additional details.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Diagnostic Efficacy of Flurpiridaz F 18 PET Myocardial Perfusion Imaging (MPI) Sensitivity Versus SPECT Myocardial Perfusion Imaging Sensitivity","description":"Diagnostic efficacy of one day rest and stress flurpiridaz F 18 PET MPI sensitivity versus SPECT MPI sensitivity in the detection of coronary artery disease (CAD) by majority rule using invasive coronary angiography as the truth standard,","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".719","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".537","spread":null}]}]}]},{"type":"SECONDARY","title":"Diagnostic Efficacy of Flurpiridaz F18 PET MPI Sensitivity Versus SPECT MPI Sensitivity in Subgroups: Pharmacologic Stress, Females and BMI>/=30.","description":"Diagnostic efficacy of flurpiridaz F18 PET MPI sensitivity versus SPECT MPI sensitivity by majority rule in the detection of CAD using invasive coronary angiography as the truth standard, , in subgroups: pharmacologic stress, females and BMI \\>/=30. Value reported is the number of true positives, i.e. True Positive: Patients with abnormal MPI and disease positive by the truth standard\n\nI","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.736","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.533","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.644","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.356","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.722","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.533","spread":null}]}]}]},{"type":"SECONDARY","title":"Diagnostic Efficacy of Flurpiridaz F18 PET MPI Specificity Versus SPECT Specificity in Subgroups: Pharmacologic Stress, Females and BMI>/=30.","description":"Diagnostic efficacy of flurpiridaz F18 PET MPI specificity versus SPECT specificity by majority rule in the detection of CAD using invasive coronary angiography as the truth standard, in subgroups: pharmacologic stress, females and BMI \\>/=30. Value represents the number of true negative, i.e. True Negative: Patients with normal MPI and disease negative by the truth standard","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".773","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".875","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".795","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".869","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".777","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".850","spread":null}]}]}]},{"type":"SECONDARY","title":"Diagnostic Performance Evaluation of Localization of CAD for Sensitivity (PETVsSPECT).","description":"Overall sensitivity of flurpiridaz F18 PET MPI in coronary territories (Qualitative Diagnosis vs. SPECT MPI by majority rule vs. truth standard (angiographic stenosis greater than or equal to 50% stenosis and confirmed MI); left descending coronary artery (LAD), left circumflex artery (LCX), right coronary artery (RCA), and non - LAD. Value reported is the number of true positives, i.e. True Positive: Patients with abnormal MPI and disease positive by the truth standard","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".495","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".333","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".398","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".251","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".596","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".476","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".627","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".464","spread":null}]}]}]},{"type":"SECONDARY","title":"Diagnostic Performance Evaluation of Localization of CAD for Specificity (PETVsSPECT).","description":"Overall specificity of flurpiridaz F18 PET MPI in Coronary Territories (Qualitative Diagnosis) vs. SPECT MPI by majority rule vs. truth standard (angiographic stenosis greater than or equal to 50% stenosis and confirmed MI); left descending coronary artery (LAD), left circumflex artery (LCX), right coronary artery (RCA), and non - LAD. Value represents the number of true negative, i.e. True Negative: Patients with normal MPI and disease negative by the truth standard","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".867","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".932","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".904","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".970","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".845","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".912","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".814","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".923","spread":null}]}]}]},{"type":"SECONDARY","title":"Diagnositic Performance Evaluation of Multivessel Disease (PETvsSPECT).","description":"Overall summary of sensitivity for identifying multi-vessel disease between flurpiridaz F18 PET MPI and SPECT MPI by majority rule vs. truth standard (angio \\>/=50% stenosis and confirmed MI). Value reported is the number of true positives, i.e. True Positive: Patients with abnormal MPI and disease positive by the truth standard","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".410","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".275","spread":null}]}]}]},{"type":"SECONDARY","title":"Diagnositic Performance Evaluation of Multivessel Disease (PETvsSPECT).","description":"Overall summary of specificity for identifying multi-vessel disease between flurpiridaz F18 PET MPI and SPECT MPI by majority rule vs. majority rule (angio \\>/=50% stenosis and confirmed MI). Value represents the number of true negative, i.e. True Negative: Patients with normal MPI and disease negative by the truth standard","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".882","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".964","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Summary of Sensitivity of PET MPI vs SPECT MPI; Image Quality Excellent or Good","description":"Overall summary of sensitivity of flurpiridaz F18 PET MPI (qualitative image quality of excellent or good) vs. SPECT MPI by majority rule vs. truth standard(angio \\>/=50% stenosis and confirmed MI). Value reported is the number of true positives, i.e. True Positive: Patients with abnormal MPI and disease positive by the truth standard","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".711","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".539","spread":null}]}]}]},{"type":"PRIMARY","title":"Diagnostic Efficacy of Flurpiridaz PET MPI Specificity Versus SPECT MPI Specificity","description":"Diagnostic efficacy of flurpiridaz PET MPI specificity versus SPECT MPI specificity by majority rule in the detection of CAD using invasive coronary angiography as the truth standard","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".762","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".868","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Summary of Specificity of PET MPI vs SPECT MPI; Image Quality of Excellent or Good","description":"Overall summary of specificity of flurpiridaz F18 PET MPI (qualitative, image quality excellent or good) vs. SPECT MPI by majority rule vs truth standard (angio \\>/=50% stenosis and confirmed MI). Value represents the number of true negative, i.e. True Negative: Patients with normal MPI and disease negative by the truth standard","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".769","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".880","spread":null}]}]}]},{"type":"SECONDARY","title":"Image Quality of Rest and Stress (PET vs SPECT).","description":"Overall summary of rest and stress image quality for flurpiridaz F18 PET MPI and SPECT MPI by majority rule. Value represents the number of subject images evaluated as excellent/good and fair/poor","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".891","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".739","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".976","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".869","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".109","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".261","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".024","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".131","spread":null}]}]}]},{"type":"SECONDARY","title":"Diagnostic Certainty in PET MPI and SPECT MPI","description":"Overall summary of diagnostic certainty in flurpiridaz F18 PET MPI and SPECT MPI by majority rule","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.862","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.138","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.799","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.201","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":20,"n":795},"commonTop":["Dyspnoea","Headache","Angina Pectoris","Electrocardiogram ST Segment Depressions","Percutaneous coronary intervention"]}}}